RxDoctor Payments Data

Derar Albashaireh

Interventional Cardiology · Pueblo, CONPI 1083902431

Payments from drug & device makers

$7,744in general payments, 2019–2025

Across 154 payments — averaging $50.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Medtronic$2K
  • Abiomed$957
  • Boston Scientific$785
  • Abbott$675
  • Shockwave Medical, Inc$171
  • plus $860 from 17 others

What the payments were for

  • Travel & lodging$2,28930%
  • Food & beverage$5,44370%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,744 in reported general payments places this provider in the 40th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$189,201
Medicare patients
765
Services billed
2,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$159,988
JardianceEmpagliflozin32$41,001
XareltoRivaroxaban32$35,331
BrilintaTicagrelor28$29,431
EntrestoSacubitril/Valsartan22$25,619
Repatha SureclickEvolocumab26$15,774
Metoprolol Succinate258$3,830
Atorvastatin Calcium179$1,983
PradaxaDabigatran Etexilate Mesylate13$1,718
ClopidogrelClopidogrel Bisulfate130$1,492
Losartan Potassium113$1,345
Carvedilol155$1,019
Furosemide135$674
Rosuvastatin Calcium59$631
Lisinopril59$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$159,988122 claims
Boehringer IngelheimJardiance, Pradaxa$58$42,71945 claims
Johnson & JohnsonXarelto$30$35,33132 claims
NovartisEntresto$15$25,61922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →